Intake of n-3 fatty acids and long-term outcome in renal transplant recipients: a post hoc analysis of a prospective cohort study

Br J Nutr. 2016 Dec;116(12):2066-2073. doi: 10.1017/S0007114516004207. Epub 2016 Dec 20.

Abstract

Supplementation with n-3 fatty acids may improve long-term outcomes of renal transplant recipients (RTR). Recent evidence suggests that EPA and DHA have different outcomes compared with α-linolenic acid (ALA). We examined the prospective associations of EPA-DHA and ALA intakes with graft failure and all-cause mortality in 637 RTR. During 3·1 years (interquartile range 2·7, 3·8) of follow-up, forty-one developed graft failure and sixty-seven died. In age- and sex-adjusted analyses, EPA-DHA and ALA intakes were not associated with graft failure. EPA-DHA intake was not significantly associated with mortality (hazard ratio (HR) 0·79; 95% CI 0·54, 1·15 per 0·1 energy% difference). ALA intake was significantly associated with mortality (HR 1·17; 95% CI 1·04, 1·31 per 0·1 energy% difference). This association remained following adjustments for BMI, proteinuria and intakes of fat, carbohydrate and protein. RTR in the highest tertile of ALA intake exhibited about 2-fold higher mortality risk (HR 2·21; 95% CI 1·23, 3·97) compared with the lowest tertile. In conclusion, ALA intake may be associated with increased mortality in RTR. Future RCT are needed to confirm these results.

Keywords: n-3 Fatty acids; ALA α-linolenic acid; En% energy percentage; HR hazard ratio; IQR interquartile range; RTR renal transplant recipients; Graft failure; Mortality; Renal transplant recipients.

Publication types

  • Comparative Study
  • Observational Study

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Cohort Studies
  • Diet / adverse effects*
  • Dietary Supplements / adverse effects*
  • Docosahexaenoic Acids / administration & dosage
  • Docosahexaenoic Acids / adverse effects
  • Docosahexaenoic Acids / therapeutic use
  • Eicosapentaenoic Acid / administration & dosage
  • Eicosapentaenoic Acid / adverse effects
  • Eicosapentaenoic Acid / therapeutic use
  • End Stage Liver Disease / surgery
  • Female
  • Follow-Up Studies
  • Graft Rejection / epidemiology
  • Graft Rejection / mortality
  • Graft Rejection / prevention & control
  • Humans
  • Kidney Transplantation / adverse effects*
  • Male
  • Middle Aged
  • Mortality
  • Netherlands / epidemiology
  • Proportional Hazards Models
  • Prospective Studies
  • Risk
  • Self Report
  • Young Adult
  • alpha-Linolenic Acid / administration & dosage
  • alpha-Linolenic Acid / adverse effects*
  • alpha-Linolenic Acid / therapeutic use

Substances

  • alpha-Linolenic Acid
  • Docosahexaenoic Acids
  • Eicosapentaenoic Acid